Posted by Michael Wonder on 05 Sep 2017
CADTH recommends olaparib following supply of results from phase 3 trial
5 September 2017 - CADTH has published its initial recommendation for olaparib for use as monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy.
The ERC rejected the initial submissions for olaparib in September last year due to uncertain clinical benefit. The submission was supported by phase 2 data.
AstraZeneca's resubmission is supported by phase 3 data (SOLO-2 trial). The ERC has now recommended the reimbursement of olaparib conditional on its cost-effectiveness being improved to an acceptable level.
